Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Yoshiya HorimotoEmi TokudaFumi MurakamiToshitaka UomoriTakanori HimuroKatsuya NakaiGotaro OrihataKotaro IijimaShinsaku TogoHideo ShimizuMitsue SaitoPublished in: Journal of translational medicine (2018)
Our data suggest that determining both mesenchymal and epithelial CTCs at baseline might be a good tool for predicting eribulin responsiveness. Evaluation of mesenchymal CTC can be considered as a parameter in larger studies, while most clinical trials are currently employing only the detection of the epithelial cellular adhesion molecule (EpCAM).
Keyphrases
- metastatic breast cancer
- epithelial mesenchymal transition
- circulating tumor cells
- clinical trial
- bone marrow
- stem cells
- transforming growth factor
- signaling pathway
- cell adhesion
- single cell
- cell therapy
- phase ii
- electronic health record
- randomized controlled trial
- big data
- circulating tumor
- loop mediated isothermal amplification
- combination therapy
- mesenchymal stem cells
- biofilm formation
- machine learning
- cystic fibrosis
- case control
- cell migration
- data analysis
- study protocol
- phase iii